Vijaya Diagnostic Centre Limited (NSE: VIJAYA | BSE: 543350)

By Raveendran R | Updated on:

Source: Vijaya Diagnostic Centre Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)

Metrics for FY 2025-26 Ended Mar 31, 2026
Profit & Loss (₹ Cr)
Revenue
₹814.20 Cr (▲ 19.5%)
Prev Year: ₹681.39 Cr
Gross Profit
₹719.52 Cr (▲ 20.6%)
Prev Year: ₹596.63 Cr
Operating Profit
₹245.08 Cr (▲ 21.0%)
Prev Year: ₹202.60 Cr
Net Profit
₹172.98 Cr (▲ 20.3%)
Prev Year: ₹143.79 Cr
Ratios & Margins (% / x)
Gross Margin
88.37 % (▲ 81 bps)
Prev Year: 87.56 %
Operating Margin
30.10 % (▲ 37 bps)
Prev Year: 29.73 %
PAT Margin
21.25 % (▲ 14 bps)
Prev Year: 21.10 %
ROCE
17.72 % (▼ 52 bps)
Prev Year: 18.24 %
ROE
18.07 % (▲ 8 bps)
Prev Year: 17.99 %
ROE (5Y Avg)
20.01 %
FY22–FY26 (5Y Avg)
ROA
11.48 % (▲ 19 bps)
Prev Year: 11.29 %
Asset Turnover
0.54x (▲ 0.01 pts)
Prev Year: 0.54x
Balance Sheet (₹ Cr)
Total Assets
₹1,507.05 Cr (▲ 18.3%)
Prev Year: ₹1,273.62 Cr
Current Assets
₹321.90 Cr (▲ 4.8%)
Prev Year: ₹307.21 Cr
Total Liabilities
₹549.90 Cr (▲ 15.9%)
Prev Year: ₹474.47 Cr
Current Liabilities
₹123.86 Cr (▼ 23.8%)
Prev Year: ₹162.61 Cr
Total Equity
₹957.15 Cr (▲ 19.8%)
Prev Year: ₹799.14 Cr
Working Capital
₹198.04 Cr (▲ 37.0%)
Prev Year: ₹144.60 Cr
Ratios & Margins (% / x)
Current Ratio
2.60x (▲ 0.71 pts)
Prev Year: 1.89x
Equity Multiplier
1.57x (▼ 0.02 pts)
Prev Year: 1.59x
Cash Flow (₹ Cr)
Operating Cash Flow
₹270.59 Cr (▲ 20.5%)
Prev Year: ₹224.47 Cr
CapEx
₹182.72 Cr (▲ 91.2%)
Prev Year: ₹95.55 Cr
Free Cash Flow
₹87.87 Cr (▼ 31.8%)
Prev Year: ₹128.92 Cr
Ratios & Margins (% / x)
FCF Margin
10.79 % (▼ 813 bps)
Prev Year: 18.92 %
Cash ROCE
19.56 % (▼ 64 bps)
Prev Year: 20.20 %
Cash ROE
28.27 % (▲ 18 bps)
Prev Year: 28.09 %

📋 Quick Facts: Company Snapshot

Attribute Disclosed Detail
Official Company Name Vijaya Diagnostic Centre Limited
Corporate Identity Number (CIN) L85195TG2002PLC039075
Stock Exchange Listing National Stock Exchange of India Limited (NSE: VIJAYA) | BSE Limited (BSE: 543350)
Date of Incorporation / Founding Year Founded in 1981 (Incorporated as a public limited company on June 05, 2002)
Founders / Key Founding Figures Dr. Sura Surendranath Reddy (Founder and Executive Chairman)
Registered Office & Corporate Headquarters No. 6-3-883/F, Ground Floor, FPA Building, Near Topaz Building, Punjagutta, Hyderabad – 500082, Telangana, India
Telephone & Official Investor Relations Email Tel: +91 040-2342 0411/12 | Email: ir@vijayadiagnostic.in / cs@vijayadiagnostic.in
Chairman / Managing Director & CEO Dr. Sura Surendranath Reddy (Executive Chairman) | Ms. Sura Suprita Reddy (Managing Director & CEO)
Chief Financial Officer (CFO) & Company Secretary (CS) Mr. Narasimha Raju K.A. (CFO w.e.f. July 09, 2026) / Mr. Ankit Shah (CFO during FY26) | Ms. Naga Vasudha Tadepalli (CS & Compliance Officer w.e.f. June 01, 2026)
Promoter & Holding Group Dr. Sura Surendranath Reddy and Promoter Family Group
Industry / Sector Classification Healthcare Services / Independent Diagnostics & Pathological Laboratories (NIC Code: 869)
Total Employees / Permanent & Contractual Workforce Split 3,244 total personnel (2,507 permanent employees and 737 other-than-permanent personnel; 3,000+ total group workforce)
Diagnostic Network & Facility Count 162 diagnostic centres across 27 cities in 6 states; 17 NABL-accredited labs and 10 NABH-accredited centres
Credit Ratings & Rating Agency Debt-free status with no outstanding debt instruments requiring credit rating
Statutory, Secretarial & Cost Auditors Statutory Auditors: M/s. B S R and Co, Chartered Accountants | Secretarial Auditors: M/s. Balaramakrishna & Associates | Cost Auditors: M/s. Santhosh & Associates
Registrar and Share Transfer Agent (RTA) KFin Technologies Limited, Selenium Tower B, Plot Nos. 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad – 500032, Telangana

🏢 The Corporate Identity: Vijaya Diagnostic Centre Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Vijaya Diagnostic Centre Limited is India’s largest consumer-focused, integrated diagnostic chain. The company operates an integrated healthcare delivery model that houses comprehensive pathology investigations and advanced radiology imaging modalities under a single roof. Founded on the principle of eliminating fragmented patient journeys, the company delivers routine, preventive, and specialized diagnostics across an integrated hub-and-spoke operating architecture.

Unlike standalone collection kiosks or hospital-dependent testing laboratories, Vijaya derives 92% of its revenues directly from individual walk-in retail consumers (B2C segment). This business-to-consumer orientation insulates the group from institutional pricing pressures and gives it commanding pricing power, high operating margins, and direct customer brand loyalty. The operational engine combines centralized high-throughput processing with localized clinical access, ensuring consistent test turnaround times and diagnostic accuracy across its regional footprint.

The company’s core value proposition revolves around four strategic pillars:

  • Unified Diagnostic Access: Integrating high-end modalities like 3 Tesla MRI, 160-slice Cardiac CT, PET-CT, Gamma Camera, and digital mammography alongside automated pathology laboratories within the same facility.
  • B2C Retail Brand Dominance: Generating approximately 92% of total operational revenue from individual walk-in patients, ensuring industry-leading cash conversion and robust working capital cycles.
  • Institutional Quality Accreditations: Operating a quality-assured testing network comprising 17 NABL-accredited laboratories and 10 NABH-accredited imaging centres.
  • Specialized Tele-radiology & AI Integration: Linking regional hub centres with a centralized pool of sub-specialized radiologists and pathologists in Hyderabad, supported by artificial intelligence tools for stone detection and dental pathology.

The Founders, Promoters & Their Legacy

Vijaya Diagnostic Centre was founded in 1981 by Dr. Sura Surendranath Reddy, a medical doctor and radiologist. Dr. Reddy earned his medical degree from Sri Venkateswara University and completed his Doctor of Medicine (M.D.) in Radiology from Osmania Medical College, Hyderabad. Recognizing that diagnostic testing in southern India was highly fragmented—forcing patients to visit disparate clinics for blood tests, X-rays, and scans—Dr. Reddy established the region’s first fully integrated diagnostic centre in Hyderabad. His medical background shaped the company’s clinical orientation, medical ethics, and standard of diagnostic reporting.

The executive leadership is supported by Ms. Sura Suprita Reddy, Managing Director and Chief Executive Officer, who joined the organization in 2003. Over her 23-year tenure, Ms. Reddy has spearheaded corporate strategy, network expansion outside the core twin-city market, digital transformation, and the initial public offering in 2021. Executive Director Mr. Sunil Chandra Kondapally holds a Bachelor’s degree in Electrical Engineering from Florida State University and brings over 24 years of operational experience, overseeing technological procurement, quality accreditations, infrastructure scale-up, and regional integration.

Mrs. Sura Geeta Reddy serves on the Board as a Non-Executive Director. Holding a law degree from Osmania University and enrolled as an advocate with the Andhra Pradesh High Court since 1986, she provides legal oversight and governance direction. Together, the promoter family controls 52.51% of the equity share capital as of March 31, 2026, preserving strategic continuity and owner-operator alignment.

The Journey: Corporate History & Key Milestones

From a single facility in Hyderabad in 1981, Vijaya Diagnostic Centre has expanded into a multi-state network. The corporate journey demonstrates sustained organic expansion supplemented by calibrated acquisitions:

  • 1981: Established first integrated diagnostic centre in Hyderabad, pioneering simultaneous pathology and basic radiology testing under one roof.
  • 1980s: Pioneered private nuclear medicine diagnostic capabilities in South India.
  • 2002: Incorporated as Vijaya Diagnostic Centre Private Limited to institutionalize diagnostic operations and scale regional infrastructure.
  • 2007: Became the first independent diagnostic provider in South India to install PET-CT imaging technology in collaboration with Wipro GE Healthcare.
  • 2020: Emerged as one of the earliest private laboratories approved by the Indian Council of Medical Research (ICMR) for COVID-19 RT-PCR testing; commissioned Telangana’s first Revolution ACT 50-slice CT scanner.
  • 2021: Successfully listed equity shares on the National Stock Exchange of India and BSE Limited following an Initial Public Offering (IPO).
  • 2023: Expanded footprint into Eastern India by launching its first hub centre in Kolkata; acquired a 100% equity stake in Pune-based P.H. Diagnostic Centre Private Limited.
  • 2025: Entered the Bengaluru healthcare market by launching two flagship hub centres in Yelahanka and HSR Layout; completed NCLT-sanctioned statutory merger of subsidiary Medinova Diagnostic Services Limited.
  • 2026: Expanded total network to 162 centres across 27 cities, deployed advanced AI-assisted imaging tools for CT KUB and dental OPG analysis, and commissioned 10 new hubs in a single financial year.

The Corporate Umbrella & Group Structure

The corporate structure of Vijaya Diagnostic Centre Limited encompasses wholly owned operating subsidiaries and specialty limited liability partnerships designed to support geographical penetration and local service delivery:

  • P H Diagnostic Centre Private Limited: A 100% wholly owned subsidiary operating an integrated network of diagnostic hubs and spokes across Pune and western Maharashtra. Acquired in FY24, the entity is fully integrated into the parent company’s operational ERP and laboratory information workflows.
  • Medinova Millennium MRI Services LLP: A 100% subsidiary partnership providing specialized magnetic resonance imaging services in Kolkata, West Bengal.
  • VDC Diagnostics (Karnataka) LLP: A 100% subsidiary partnership entity in Karnataka, currently undergoing statutory strike-off under the Limited Liability Partnership Act, 2008, as operations have been streamlined under the parent corporate entity.
  • Amalgamation of Medinova Diagnostic Services Limited: During the reporting period, the group finalized the statutory merger of Medinova Diagnostic Services Limited into Vijaya Diagnostic Centre Limited under Sections 230 to 232 of the Companies Act, 2013, sanctioned by the Hon’ble NCLT Hyderabad Bench on October 13, 2025.

⚙️ The Business Engine: Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

In accordance with Ind AS 108 Operating Segments, the Group’s Chief Operating Decision Maker (CODM)—comprising the Executive Chairman and the Managing Director & CEO—evaluates performance as a single operating segment: “Diagnostic Services”. Discrete financial information is reviewed across clinical streams, specifically Pathology and Radiology, alongside customer service delivery channels.

Pathology services contributed 63% of total revenue from operations in FY 2025-26, while Radiology accounted for 37%. This balanced split provides revenue defensibility, as high-margin routine pathology tests provide recurring cash flow while capital-intensive radiology modalities act as clinical anchors for specialist doctor referrals.

Clinical Stream / Operating Modality FY 2025-26 Revenue (₹ in Crores) FY 2024-25 Revenue (₹ in Crores) % Share of Total Revenue (FY26) Operational Role & Clinical Scope Latest YoY (%)
Pathology Investigations 512.95 429.28 63.00% Clinical biochemistry, haematology, histopathology, molecular biology, cytogenetics, and microbiology. +19.49%
Radiology & Advanced Imaging 301.25 252.11 37.00% 3T MRI, 160-slice Cardiac CT, PET-CT, Gamma Camera nuclear medicine, ultrasound, DEXA, mammography, and digital X-ray. +19.49%
Total Revenue from Operations 814.20 681.39 100.00% Integrated comprehensive diagnostic operations across 162 network centres. +19.49%

The Product & Service Catalog (with Operational KPIs & Order Book)

Vijaya Diagnostic Centre offers a testing catalog spanning basic routine diagnostics to high-end molecular pathology and tertiary radiology. The testing portfolio is accessed through retail walk-in visits, corporate executive wellness check-ups, and specialized home sample collections.

Operational throughput and volume expansion drove operational performance during FY 2025-26:

  • Patient Footfall Volume: Total patient footfalls reached 4.68 million individuals, expanding 11.7% YoY from 4.19 million in FY 2024-25.
  • Total Diagnostic Tests Processed: Laboratory and imaging test volumes expanded 14.4% YoY to 16.92 million tests compared to 14.79 million in the preceding year.
  • Revenue Realisation Metrics: Average revenue per test increased to ₹481 (up from ₹461 in FY25), while average revenue per footfall rose to ₹1,740 (up from ₹1,627 in FY25), driven by higher testing intensity per patient and increased uptake of comprehensive preventive packages.
  • Tests Per Footfall Ratio: Deepened clinical investigation per visit led to an average of 3.62 tests per patient footfall compared to 3.53 in FY25.
  • Preventive Wellness Contribution: Preventive healthcare packages generated 14.8% of gross operational revenues, expanding from approximately 8% in the pre-COVID era.
  • Customer Concentration Profile: In line with Ind AS 108 disclosures, no single customer accounts for 10% or more of total group revenue, reflecting zero customer concentration risk.
  • Order Book & Sourcing Split: As a retail healthcare service provider, the company does not operate a manufacturing order book. Diagnostic reagents, chemicals, and consumable kits are procured under annual volume-tier agreements, with indigenous and local supplies complemented by imported specialized assay kits and equipment spares.

The Names You Know: Key Brands & Flagship Portfolio

The company markets its clinical capabilities through focused healthcare delivery brands, digital applications, and proprietary service suites across its target urban and semi-urban markets.

Brand / Product Name Category / Business Segment Target Market & Key Positioning
Vijaya Diagnostic Centre Flagship Retail Diagnostic Chain Core consumer retail brand positioned as a trusted, one-stop integrated pathology and radiology provider across Telangana, Andhra Pradesh, and Karnataka.
Vijaya PH Regional Integrated Brand (Maharashtra) Dual-branded network across Pune metropolitan region delivering specialized radiology and pathology, transitioning legacy PH Diagnostics centres onto Vijaya’s systems.
V-Gyan Enterprise Learning & Clinical Management Internal enterprise LMS platform providing continuous technical training, medical protocols, compliance education, and soft skills certification for over 2,100 personnel.
Vijaya Health App Digital Consumer & Home Diagnostics Omnichannel mobile platform offering digital report access, electronic prescription uploads, doctor appointment scheduling, and temperature-controlled home collection.
Executive Wellness Packages Preventive Health Diagnostics Curated corporate and individual preventive health packages combining multi-organ blood panels with cardiac CT calcium scoring, mammography, ultrasound, and whole-body MRI.

Mapping the Domestic & Global Reach (India vs. Exports)

Vijaya Diagnostic Centre operates entirely within the domestic Indian healthcare ecosystem. Under Section A (Item 18) of the Business Responsibility and Sustainability Report, export revenues stand at Nil, with 100% of diagnostic turnover generated from operations within India.

Geographical Market FY 2025-26 Revenue (₹ in Crores) FY 2024-25 Revenue (₹ in Crores) % Share of Total Revenue (FY26) Operating Network Footprint Latest YoY (%)
Domestic Operations (India) 814.20 681.39 100.00% 162 centres across Telangana, Andhra Pradesh, Maharashtra, Karnataka, West Bengal, and NCR. +19.49%
International / Export Revenue 0.00 0.00 0.00% No international centres or diagnostic cross-border service exports. N/M
Total Operational Revenue 814.20 681.39 100.00% Direct consumer and institutional operations across 6 states. +19.49%

The Brick & Mortar Footprint: Infrastructure, Labs & Regional Hubs

The company operates 162 diagnostic centres across 27 cities and towns, structured around high-capacity central processing laboratories, tertiary diagnostic hubs, and spoke collection centres:

  • Telangana & Andhra Pradesh (Core Markets): Market leadership anchored by flagship reference hubs in Himayat Nagar and Panjagutta (Hyderabad), supported by large-format hubs in Tier-2/3 district headquarters including Khammam (10,000 sq. ft.), Nandyal (8,000 sq. ft.), Tirupati, Kurnool, Vijayawada, Guntur, Rajahmundry, Visakhapatnam, Nizamabad, Karimnagar, and Hanamkonda.
  • West Bengal: Fast-growing network encompassing seven operational hubs, including Kolkata flagship facilities (VIP Road, Kasba, Phoolbagan, Southern Avenue) and Tier-2 district hubs in Krishnanagar, Barasat, and Diamond Harbour equipped with 3 Tesla MRI systems.
  • Karnataka: Two high-capacity metropolitan hubs established in Bengaluru at Yelahanka (7,500 sq. ft.) and HSR Layout (8,500 sq. ft.), alongside a flagship 10,000+ sq. ft. comprehensive facility underway at Bannerghatta–JP Nagar housing a digital PET-CT with 160-slice cardiac CT and wide-bore Omega 3T MRI.
  • Maharashtra (Pune Cluster): Regional network of 19 centres including large-format tertiary hubs in Kalyani Nagar (~10,500 sq. ft.) and Ambegaon, supported by spoke centres across Pimpri-Chinchwad, Aundh, Kothrud, Hadapsar, and Sinhagad Road.
  • Central Automated Processing Hub: Fully automated central laboratory in Panjagutta, Hyderabad, featuring a continuous track automation system designed to minimize manual sample handling and compress turnaround times.

📊 The Financial Health: The Numbers Simplified

Multi-Year Financial Highlights (₹ in Crores)

The historical performance disclosed in the company’s financial indicators illustrates consistent top-line compounding, margin discipline, and zero-debt balance sheet expansion across five consecutive fiscal years following its initial public offering.

Financial & Operational Metric FY 2025-26 FY 2024-25 FY 2023-24 FY 2022-23 FY 2021-22 Latest YoY (%)
Revenue from Operations (₹ Cr) 814.20 681.40 547.80 459.20 462.40 +19.49%
EBITDA (₹ Cr) 336.90 273.20 220.90 182.00 203.70 +23.32%
EBITDA Margin (%) 41.40% 40.10% 40.30% 39.60% 44.10% –
Profit After Tax (PAT) (₹ Cr) 173.00 143.80 118.80 84.60 109.70 +20.31%
Basic Earnings Per Share (₹) 16.81 13.99 11.62 8.29 10.76 +20.16%
Pre-Tax Return on Capital Employed (RoCE %) 17.72% 18.24% 26.00% 26.00% 46.00% –
Return on Equity (RoE %) 18.07% 17.99% 20.00% 17.00% 27.00% –
Surplus Treasury Cash & Bank Balances (₹ Cr) 286.90 206.70 185.10 255.40 246.50 +38.80%
Operational Diagnostic Centres (Count) 162 151 145 121 95 +7.28%
Annual Patient Footfalls (Millions) 4.68 4.19 3.55 3.18 3.62 +11.69%
Total Diagnostic Tests Processed (Millions) 17.72% 18.24% 11.89 10.05 9.32 –
Operating Cash Flow / EBITDA Conversion (%) 80.00% 82.00% 83.00% 90.00% 78.00% –

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

Consolidated revenue from operations for FY 2025-26 expanded 19.49% to ₹814.20 Crores compared to ₹681.39 Crores in FY 2024-25. Total revenue expansion was primarily volume-driven, with footfalls growing 11.7% and diagnostic tests expanding 14.4%. High operating leverage across established centres, combined with rapid breakeven timelines at newly commissioned regional hubs in West Bengal and Bengaluru, allowed EBITDA to expand 23.32% to ₹336.90 Crores, lifting consolidated EBITDA margin to 41.38%.

Operating profit (EBIT) stood at ₹245.11 Crores compared to ₹202.62 Crores in FY25, translating to an Operating Margin of 30.10%. Finance costs rose to ₹33.23 Crores, driven predominantly by Ind AS 116 lease interest of ₹30.68 Crores associated with rapid retail real estate expansion. Profit after tax rose 20.30% to ₹172.98 Crores compared to ₹143.79 Crores in FY 2024-25.

Statement of Profit and Loss Line Item FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Revenue from operations 814.20 681.39 +19.49%
Other income 20.80 18.32 +13.54%
Total Income 835.00 699.71 +19.34%
Cost of materials consumed 94.68 84.76 +11.70%
Employee benefits expense 130.74 112.15 +16.58%
Finance costs 33.23 26.74 +24.27%
Depreciation and amortisation expense 91.82 70.60 +30.06%
Other expenses 251.84 211.26 +19.21%
Total Expenses 602.32 505.52 +19.15%
Profit before exceptional items and tax 232.68 194.19 +19.82%
Exceptional items 0.00 1.03 -100.00%
Profit Before Tax 232.68 193.16 +20.46%
Current tax 50.68 41.18 +23.07%
Deferred tax 9.03 8.19 +10.26%
Total tax expense 59.70 49.37 +20.92%
Profit for the Year (PAT) 172.98 143.79 +20.30%
Other Comprehensive Income (net of tax) 0.65 0.00 N/M
Total Comprehensive Income for the Year 173.63 143.80 +20.74%

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

The consolidated balance sheet of Vijaya Diagnostic Centre remains debt-free, with zero non-current and current borrowings from banks or financial institutions. Total assets grew to ₹1,507.05 Crores as at March 31, 2026, compared to ₹1,273.62 Crores in the preceding fiscal year. Growth in the non-current asset base was propelled by substantial investments in high-end medical equipment, raising Property, Plant, and Equipment to ₹562.47 Crores and Right-of-Use assets to ₹367.15 Crores.

Total Equity (Net Worth) stood at ₹957.15 Crores, backed by retained earnings of ₹863.62 Crores and securities premium of ₹72.22 Crores. Total Liabilities stood at ₹549.90 Crores, comprising ₹426.03 Crores of non-current liabilities and ₹123.86 Crores of current liabilities. Under the IndianCompanies analytical framework, Total Debt is ₹0.00 Crores, yielding a Debt-to-Equity ratio of 0.00x. Total Capital Employed expanded to ₹1,383.19 Crores (Total Assets of ₹1,507.05 Crores less Total Current Liabilities of ₹123.86 Crores).

Working capital management remained efficient throughout the fiscal period:

  • Inventory Days: Operating at approximately 19 days of material consumption (Inventory of ₹4.89 Crores against Annual Materials Consumed of ₹94.68 Crores).
  • Debtors Turnover & Collection: Average receivable collection cycle stood at 9 days of operational revenue (Trade Receivables of ₹20.86 Crores against Operational Turnover of ₹814.20 Crores).
  • Current Ratio: The standalone current ratio strengthened to 2.77x (consolidated at 2.60x), driven by a sharp reduction in capital equipment payables from ₹83.11 Crores to ₹38.22 Crores.
Consolidated Balance Sheet Items As at March 31, 2026 (₹ in Crores) As at March 31, 2025 (₹ in Crores) Latest YoY (%)
Non-Current Assets
Property, plant and equipment 562.47 446.87 +25.87%
Capital work-in-progress 34.29 70.26 -51.20%
Right-of-use assets 367.15 276.84 +32.62%
Goodwill 119.20 119.20 0.00%
Other intangible assets 20.44 21.89 -6.62%
Intangible assets under development 0.79 0.00 N/M
Non-current investments 0.04 0.04 0.00%
Other non-current financial assets 48.09 16.49 +191.63%
Other tax assets (net) 0.25 1.20 -79.17%
Other non-current assets 32.43 13.62 +138.11%
Total Non-Current Assets 1,185.15 966.41 +22.63%
Current Assets
Inventories 4.89 4.93 -0.81%
Current investments (Mutual funds) 228.38 184.60 +23.72%
Trade receivables 20.86 14.76 +41.33%
Cash and cash equivalents 39.68 12.79 +210.24%
Bank balances other than cash and cash equivalents 13.06 36.08 -63.80%
Other current financial assets 8.01 47.79 -83.24%
Other current assets 7.02 6.25 +12.32%
Total Current Assets 321.90 307.21 +4.78%
TOTAL ASSETS 1,507.05 1,273.62 +18.33%
Equity
Equity share capital 10.29 10.26 +0.29%
Other equity 946.86 788.88 +20.03%
Total Equity (Net Worth) 957.15 799.14 +19.77%
Non-Current Liabilities
Non-current borrowings 0.00 0.00 N/M
Non-current lease liabilities 400.03 296.41 +34.96%
Non-current provisions 11.02 9.87 +11.65%
Deferred tax liabilities (net) 14.52 5.28 +175.00%
Other non-current liabilities 0.47 0.30 +56.67%
Total Non-Current Liabilities 426.03 311.86 +36.61%
Current Liabilities
Current borrowings 0.00 0.00 N/M
Current lease liabilities 22.56 23.16 -2.59%
Trade payables – Micro and small enterprises 2.80 1.09 +156.88%
Trade payables – Other creditors 34.77 32.04 +8.52%
Other current financial liabilities 49.14 92.45 -46.85%
Other current liabilities 5.34 4.43 +20.54%
Current provisions 8.32 5.98 +39.13%
Current tax liabilities (net) 0.94 3.45 -72.75%
Total Current Liabilities 123.86 162.61 -23.83%
Total Liabilities 549.90 474.47 +15.90%
TOTAL EQUITY AND LIABILITIES 1,507.05 1,273.62 +18.33%

Cash Flow: Tracking the Money Movement

Cash conversion remained high during FY 2025-26, supported by retail cash-and-carry consumer collections. Cash flow from operating activities reached ₹270.59 Crores, an increase of 20.55% over ₹224.47 Crores in FY 2024-25. Operating cash flow conversion against EBITDA was 80.32%, providing self-funded liquidity for network rollouts.

Net cash used in investing activities was ₹174.22 Crores, primarily directed toward capital equipment purchases of ₹182.72 Crores, offset by net bank deposit redemptions of ₹31.20 Crores and interest income received of ₹6.43 Crores. Financing cash outflows totaled ₹69.49 Crores, comprising lease liability principal payments of ₹21.46 Crores, lease finance cost payments of ₹30.68 Crores, and dividend payments of ₹20.54 Crores, offset by employee stock option exercise inflows of ₹3.20 Crores. Cash and cash equivalents closed at ₹39.68 Crores.

Consolidated Cash Flow Statement Component FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Operating profit before working capital changes 339.66 271.81 +24.96%
Net working capital adjustments (16.83) (7.43) +126.51%
Cash generated from operations 322.83 264.39 +22.10%
Direct income taxes paid (net) (52.24) (39.92) +30.86%
Net Cash generated from Operating Activities (A) 270.59 224.47 +20.55%
Purchase of Property, Plant and Equipment (CapEx) & Intangibles 182.72 95.55 +91.23%
Proceeds from sale of property, plant and equipment 17.72% 18.24% –
Net investments in mutual funds and bonds (31.97) (63.61) -49.74%
Net redemptions / (investments) in bank deposits (>3 months) 31.20 (28.94) N/M
Interest received 6.43 3.28 +96.04%
Net Cash used in Investing Activities (B) (174.22) (181.88) -4.21%
Proceeds from issue of equity shares under ESOP 17.72% 18.24% –
Payment of equity dividend (20.54) (10.26) +100.19%
Principal repayment of lease liabilities (21.46) (21.97) -2.32%
Finance costs paid (lease interest and bank charges) (30.68) (23.92) +28.26%
Net Cash used in Financing Activities (C) (69.49) (52.05) +33.51%
Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C) 26.88 (9.45) N/M
Cash and cash equivalents at the beginning of the year 12.79 22.25 -42.52%
Cash and Cash Equivalents at the End of the Year 39.68 12.79 +210.24%

Funding the Future: CapEx, CWIP, R&D & Foreign Exchange

Capital investments during the financial year reached record levels as the company accelerated its expansion outside its core Telangana and Andhra Pradesh base:

  • Capital Expenditure Deployed: Gross cash additions to Property, Plant, Equipment, Right-of-Use assets, and Intangibles totaled ₹182.72 Crores, reflecting the simultaneous commissioning of 10 new hub centres and leasehold facility improvements.
  • Capital Work-in-Progress (CWIP): Pending capitalization CWIP stood at ₹34.29 Crores as at March 31, 2026, comprising upcoming diagnostic centres with ₹29.51 Crores aged under one year.
  • Research & Development Expenditure: In line with Section 134(3)(m) statutory disclosures, direct R&D expenditure is Nil, as clinical development is conducted through real-world AI diagnostic deployments and ongoing medical education partnerships.
  • Foreign Exchange Earnings & Outgo: Under statutory disclosures in Annexure III, Foreign Exchange Earnings stood at ₹0.00 Crores (Nil), while Foreign Exchange Outgo was ₹0.10 Crores (₹10,01,560) for overseas service subscriptions and testing consumables, down from ₹0.17 Crores in FY25.

👥 Power & Control: Corporate Governance, Leadership & Ownership

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

The governance structure complies with Regulation 17 of the SEBI Listing Regulations. As of March 31, 2026, the Board comprises 10 directors: three Executive Directors, one Non-Executive Non-Independent Director, and six Non-Executive Independent Directors, including two women Independent Directors.

Name of Director / KMP Designation / Role DIN Category
Dr. Sura Surendranath Reddy Founder and Executive Chairman 00108599 Promoter & Executive Director
Ms. Sura Suprita Reddy Managing Director & Chief Executive Officer 00263618 Promoter & Executive Director
Mr. Sunil Chandra Kondapally Executive Director 01409332 Promoter & Executive Director
Mrs. Sura Geeta Reddy Non-Executive Director 01073233 Promoter & Non-Executive Director
Mr. Satyanarayana Murthy Chavali Independent Director (Audit Committee Chairman) 00142138 Non-Executive Independent Director
Mr. Shekhar Prasad Singh Independent Director 00969209 Non-Executive Independent Director
Dr. Duvvur Nageshwar Reddy Independent Director 00324725 Non-Executive Independent Director
Dr. Manjula Anagani Independent Director (Padma Shri Awardee) 03501757 Non-Executive Independent Director
Mr. Ravi Shankararamiah Independent Director (Senior Advocate) 00180746 Non-Executive Independent Director
Dr. Sasikala Paruchuri Kola Independent Director (Consultant Gynaecologist) 00129614 Non-Executive Independent Director
Mr. Ankit Shah Chief Financial Officer (KMP during FY26) Not Applicable Key Managerial Personnel
Mr. Narasimha Raju K.A. Chief Financial Officer (Appointed w.e.f. July 09, 2026) Not Applicable Key Managerial Personnel
Ms. Naga Vasudha Tadepalli Company Secretary & Compliance Officer Not Applicable Key Managerial Personnel

Who Owns the Stock? Shareholding Pattern

The issued, subscribed, and paid-up equity share capital of the company as of March 31, 2026, stands at ₹10,28,96,728 divided into 10,28,96,728 equity shares of face value of ₹1 each. Promoters hold 52.51% of the total equity, with institutional funds accounting for 42.45%.

Shareholder Category Number of Folios / Cases Total Shares Held % of Paid-up Capital
Promoter Individual (Dr. S. Surendranath Reddy) 1 3,31,66,309 32.24%
Promoter Group Entities & Relatives 9 2,08,66,847 20.27%
Mutual Funds 24 2,99,05,125 29.07%
Foreign Portfolio Investors (FPIs) 126 1,37,66,187 13.38%
Resident Individuals (Public) 59,750 35,72,708 3.47%
Insurance Companies & Financial Institutions 4 5,25,032 0.51%
Alternative Investment Funds (AIF) 7 3,69,893 0.36%
Non-Resident Indians (NRIs) 1,683 2,40,756 0.23%
Bodies Corporate 295 1,76,946 0.17%
Employees 101 1,26,756 0.12%
Trusts, HUF, Clearing Members & NBFCs 946 1,80,169 0.18%
Total Shareholding 62,946 10,28,96,728 100.00%

Major institutional and individual shareholders holding more than 5% of the paid-up equity share capital as disclosed in Note 10(a)(iii):

  • Dr. Sura Surendranath Reddy (Promoter): 3,31,66,309 shares (32.23% holding).
  • Ms. Sura Suprita Reddy (Promoter MD & CEO): 89,71,660 shares (8.72% holding).
  • Mr. Sunil Chandra Kondapally (Promoter Executive Director): 77,75,843 shares (7.56% holding).
  • Kotak Small Cap Fund: 71,90,396 shares (6.99% institutional holding).
  • Nippon Life India Trustee Limited: 71,24,796 shares (6.92% institutional holding).

🗺️ The Corporate Family Tree: Group Structure & Strategic Investments

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

The operational and financial standing of the subsidiary undertakings as disclosed in Form AOC-1 for the year ended March 31, 2026, reflects their integration into regional market strategies.

Entity Name Relationship Type Country % Shareholding Turnover (₹ in Crores) Profit / (Loss) After Tax (₹ in Crores)
P H Diagnostic Centre Private Limited Wholly Owned Subsidiary India 100.00% 47.66 (0.77)
Medinova Millennium MRI Services LLP Subsidiary Partnership India 100.00% 2.36 0.97
VDC Diagnostics (Karnataka) LLP Subsidiary Partnership India 100.00% 0.00 0.15

Strategic Investments, Credit Facilities & Contingent Liabilities

The company maintains a liquid treasury balance deployed across AAA-rated index funds, liquid debt mutual funds, and short-term bank fixed deposits:

  • Treasury Portfolio: Current investments in quoted debt, money market, and corporate bond mutual funds stood at ₹228.38 Crores as of March 31, 2026. Non-current strategic unquoted equity investments comprise ₹0.04 Crores in C.R. Broadcasting Hyderabad Limited.
  • Borrowing Arrangements & Bank Facilities: The company operates with zero long-term and short-term debt borrowings, maintaining cash reserves of ₹286.90 Crores across cash, bank deposits, and mutual funds.
  • Contingent Liabilities: Total contingent tax claims disputed and not acknowledged as debt aggregate to ₹0.15 Crores (comprising ₹0.02 Crores in service tax and ₹0.13 Crores in GST, of which ₹0.02 Crores has been deposited under protest).
  • Capital Commitments: Estimated amount of capital contracts remaining to be executed on capital account and not provided for stood at ₹30.05 Crores (net of capital advances).

🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans

Competitive Advantages & Economic Moats

Vijaya Diagnostic Centre maintains several structural differentiators in the Indian diagnostic sector:

  • One-Stop Integrated Footprint: Combining pathology and high-end imaging creates convenience for retail patients and increases revenue per patient footfall (₹1,740) relative to standalone pathology kiosks.
  • Retail Brand Loyalty (92% B2C): Direct relationships with walk-in consumers provide price resilience and shield margins from hospital cuts or B2B tender bidding.
  • Sub-Specialty Medical Pool: A team of over 400 specialized and super-specialized radiologists and pathologists enables complex sub-specialty reads across neuro, cardiac, and musculoskeletal imaging via tele-radiology.
  • Rapid Centre Breakeven Discipline: Newly commissioned hub centres in Krishnanagar and Barasat reached operational breakeven within three quarters, while Tier-2 hubs in Khammam, Nandyal, and Yelahanka achieved breakeven in two quarters.

What Could Go Wrong? Key Challenges & Business Risks

The enterprise risk framework detailed in the Management Discussion and Analysis highlights operational and sectoral risks:

  • Geographic Concentration Risk: While expansion into West Bengal, Pune, and Bengaluru is progressing, the majority of cash generation remains anchored in Hyderabad and Andhra Pradesh.
  • Talent Attrition & Radiologist Scarcity: India has an estimated deficit of nearly 15,000 radiologists. Attracting and retaining specialized diagnostic clinicians across semi-urban clusters requires competitive compensation.
  • Technology Obsolescence & Maintenance: Advanced medical modalities—such as 3T MRI, PET-CT, and automated track laboratories—require high upfront capital and ongoing maintenance contracts, making capacity utilization critical to preventing margin dilution.
  • Regulatory & Compliance Shifts: Compliance across multiple state regulations, including the PCNDT Act, Atomic Energy Regulatory Board (AERB) radiation rules, bio-medical waste protocols, and upcoming National Labour Code rules (which resulted in an incremental provision of ₹0.92 Crores during the year).

The Next Chapter: Growth, Network Rollout & CapEx Initiatives

For FY 2026-27, the company has outlined a calibrated expansion plan to deepen network density:

  • New Centre Commissioning Targets: Management plans to commission 8 to 9 new diagnostic hub centres alongside 10 to 12 spoke collection centres in FY27.
  • Bengaluru Expansion: Capitalizing on the rapid breakeven of the Yelahanka and HSR Layout facilities, the group has finalized the lease for a 10,000+ sq. ft. flagship facility in Bannerghatta–JP Nagar, introducing digital PET-CT and wide-bore Omega 3T MRI systems.
  • Deepening East India Footprint: Scaling spoke collection centres around the 5 new hub facilities operationalized across West Bengal during FY26 to lift pathology volumes and asset turns.
  • Laboratory Automation: Commissioning a fully automated total laboratory automation (TLA) track system at the Panjagutta reference facility in Hyderabad to expand specimen processing capacity and support long-term network growth.

The Verdict: Strategic Outlook & Conclusion

Vijaya Diagnostic Centre Limited has demonstrated consistent performance over the five years since its 2021 IPO, generating a 17% revenue CAGR and expanding network size to 162 centres while maintaining EBITDA margins above 40%. The combination of a debt-free balance sheet, over ₹286.90 Crores in liquid surplus cash, and an integrated B2C service delivery model positions the company to continue its multi-state expansion across both southern and eastern growth corridors.

Frequently Asked Questions (FAQs) About Vijaya Diagnostic Centre

Q1: What is the core business model of Vijaya Diagnostic Centre Limited?

Vijaya Diagnostic Centre operates an integrated medical diagnostic model offering pathology tests and advanced radiology imaging (such as 3T MRI, CT scans, PET-CT, and ultrasound) under one roof. Unlike many listed peers that focus on B2B sample routing, Vijaya generates approximately 92% of its revenues directly from individual walk-in retail consumers (B2C segment).

Q2: What were the company’s financial results for FY 2025-26?

In FY 2025-26, the company reported consolidated Revenue from Operations of ₹814.20 Crores (a 19.49% YoY increase), EBITDA of ₹336.90 Crores (with a 41.38% EBITDA margin), and Profit After Tax (PAT) of ₹172.98 Crores (a 19.49% YoY increase). Basic EPS stood at ₹16.81.

Q3: Who manages and controls Vijaya Diagnostic Centre?

The company was founded in 1981 by medical radiologist Dr. Sura Surendranath Reddy, who serves as Executive Chairman. Daily executive management is led by Managing Director & CEO Ms. Sura Suprita Reddy, alongside Executive Director Mr. Sunil Chandra Kondapally. The promoter group holds 52.51% of the total equity share capital as of March 31, 2026.

Q4: How large is Vijaya’s physical network and what is its geographic presence?

As of March 31, 2026, the company operates 162 diagnostic centres across 27 cities and towns in six states: Telangana, Andhra Pradesh, West Bengal, Maharashtra, Karnataka, and the National Capital Region (NCR). The network includes 17 NABL-accredited testing laboratories and 10 NABH-accredited imaging facilities.

Q5: What is the company’s debt position and future expansion strategy?

Vijaya Diagnostic Centre is debt-free with zero bank borrowings and surplus treasury cash and mutual fund investments of ₹286.90 Crores. For FY 2026-27, the company plans to commission 8 to 9 new hub centres and 10 to 12 spoke facilities, with major expansions underway in Bengaluru, West Bengal, and the twin cities of Hyderabad and Secunderabad.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.vijayadiagnostic.com